查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1772227

美國球囊瓣環成形設備市場規模、佔有率、應用趨勢分析報告、最終用途、細分市場預測，2025-2033

U.S. Balloon Valvuloplasty Devices Market Size, Share & Trends Analysis Report By Application (Aortic Valve Stenosis, Pulmonary Valve Stenosis), By End Use (Hospitals, Ambulatory Surgical Centers), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國球囊瓣環成形術設備市場價值將達到 8.201 億美元，預計 2025 年至 2033 年的複合年成長率為 3.4%。

風濕性心臟疾病(RHD) 是一種嚴重的心血管疾病，由風濕熱發作後心臟瓣膜的永久性損傷引起。在美國，瓣膜性心臟病的盛行率持續上升，尤其是在老年人群中，估計影響到 2.5% 的人口，因此對有效治療方案的需求巨大。

風濕性心臟病 (RHD) 通常會導致嚴重的瓣膜功能障礙，通常需要球囊瓣環成形等介入性治療來恢復正常的瓣膜功能並改善患者的預後。微創手術的進步以及人們對早期瓣膜疾病干預意識的提高推動了這種日益成長的臨床需求，並正在推動市場擴張。技術創新持續推動市場成長。正如愛思唯爾公司 (Elsevier Inc.) 於 2023 年 8 月發表的一篇論文所強調的那樣，球囊主動脈瓣瓣環成形(BAV) 的最新進展顯著提升了其臨床價值，尤其是在作為經導管主動脈瓣置換術術 (TAVR) 前的過渡治療時。

在過去的二十年中，球囊導管技術取得了顯著進展，終端使用者和設計方面的改進也有助於提高手術成功率。此外，心室起搏技術和動脈通路方法（例如增強經皮經皮股動脈通路）的改進降低了球囊導管（BAV）的相關風險，使手術更加安全可靠。這些技術突破重新點燃了人們對球囊導管（BAV）的興趣，尤其是將其作為不適用於TAVR的患者的短期治療選擇。

技術進步提高了球囊主動脈瓣瓣環成形(BAV) 的可行性，臨床醫生也越來越熟練地操作大直徑球囊並管理整個手術流程。球囊導管設計精度的提升和現代影像工具的進步改善了手術效果。然而，關於 BAV 的長期療效仍然存在疑問，尤其是在經導管主動脈瓣置換術(TAVR) 不斷取得成功的情況下，人們對該手術在現代治療策略中的作用提出了質疑。

法規透過維護安全性、有效性和品質標準，在塑造美國市場方面發揮關鍵作用。雖然嚴格的監管標準可能會減緩核准流程、延遲產品上市並抑制創新，但它們也能增強病患信心並穩定設備效能。從長遠來看，這些法規確保只有經過充分測試、可靠的設備才能核准用於臨床，以支持市場成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國瓣環成形設備市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國球囊瓣環成形術器械市場的分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國瓣環成形術設備市場：按應用的估計和趨勢分析

  • 按用途細分儀表板
  • 美國瓣環成形術器械市場：按應用進行的變化分析
  • 美國球囊瓣環成形術器械市場規模及應用趨勢分析（2021-2033）
  • 主動脈瓣狹窄
  • 肺動脈狹窄

第5章美國瓣環成形術設備市場：依最終用途的估計和趨勢分析

  • 依最終用途細分儀表板
  • 美國瓣環成形術器械市場：依最終用途進行的變化分析
  • 美國球囊瓣環成形術器械市場規模及應用趨勢分析（2021-2033）
  • 醫院
  • 門診手術中心（ASC）
  • 心導管實驗室

第6章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 2024年公司市場佔有率分析
  • 公司簡介/上市公司
    • B. Braun Interventional Systems, Inc
    • BD
    • Edwards Lifesciences Corporation
    • Boston Scientific Corporation
    • Getinge
    • TORAY INTERNATIONAL, INC.
    • Stryker
    • BrosMed Medical Co., Ltd.
    • Medtronic
    • Terumo Corporation
Product Code: GVR-4-68040-641-9

Market Size & Trends:

The U.S. balloon valvuloplasty devices market size was estimated at USD 820.1 million in 2024 and is expected to grow at a CAGR of 3.4% from 2025 to 2033. Rheumatic heart disease (RHD) is a critical cardiovascular disorder caused by permanent damage to the heart valves following an episode of rheumatic fever. As the prevalence of valvular heart diseases continues to rise across the U.S., affecting an estimated 2.5% of the population, particularly among older adults, the need for effective treatment options has grown substantially.

RHD often results in severe valve dysfunction, which frequently necessitates interventional procedures such as balloon valvuloplasty to restore normal valve function and improve patient outcomes. This growing clinical need drives market expansion, fueled by advancements in minimally invasive procedures and increasing awareness of early valve disease intervention. Technological innovations continue to drive market growth. As highlighted in a publication by Elsevier Inc. in August 2023, recent advancements in balloon aortic valvuloplasty (BAV) have significantly enhanced its clinical value, especially when used as a transitional therapy before transcatheter aortic valve replacement (TAVR).

Over the past 20 years, substantial progress has been made in balloon catheter technology, including developing improved End Uses and designs contributing to better procedural success rates. In addition, improvements in ventricular pacing techniques and arterial access methods, such as enhanced percutaneous femoral access, have helped lower the risks associated with BAV, making the procedure safer and more reliable. These technological breakthroughs have renewed interest in BAV, particularly as a short-term option for patients who are not immediate candidates for TAVR.

Advancements in technology have enhanced the feasibility of balloon aortic valvuloplasty (BAV), with clinicians becoming increasingly proficient in managing large-bore access and the overall procedural workflow. Improved balloon catheter designs and the accuracy of modern imaging tools have led to better procedural outcomes. Nonetheless, questions remain about the long-term effectiveness of BAV, especially as the growing success of transcatheter aortic valve replacement (TAVR) continues to challenge the procedure's role in contemporary treatment strategies.

Regulations play a critical role in shaping the U.S. market by upholding safety, effectiveness, and quality benchmarks. While strict regulatory standards can slow down the approval process, potentially delaying product launches and hindering innovation, they also contribute to greater patient trust and consistent device performance. In the long run, these regulations support market growth by ensuring that only thoroughly tested and reliable devices are approved for clinical use.

U.S. Balloon Valvuloplasty Devices Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. balloon valvuloplasty devices market report based on treatment and end use:

  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Aortic Valve Stenosis
  • Pulmonary Valve Stenosis
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Cardiac Catheterization Labs

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End Use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End Use outlook
  • 2.3. Competitive scenario

Chapter 3. U.S. Balloon Valvuloplasty Devices Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Balloon Valvuloplasty Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Balloon Valvuloplasty Devices Market: Application Estimates & Trend Analysis

  • 4.1. Application Segment Dashboard
  • 4.2. U.S. Balloon Valvuloplasty Devices Market: Application Movement Analysis
  • 4.3. U.S. balloon valvuloplasty devices market Size & Trend Analysis, By Application, 2021 to 2033 (USD Million)
  • 4.4. Aortic Valve Stenosis
    • 4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pulmonary Valve Stenosis
    • 4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Balloon Valvuloplasty Devices Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. U.S. Balloon Valvuloplasty Devices Market: End Use Movement Analysis
  • 5.3. U.S. balloon valvuloplasty devices market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Ambulatory Surgical Centers (ASCs)
    • 5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Cardiac Catheterization Labs
    • 5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Company market share analysis, 2024
  • 6.4. Company Profiles/Listing
    • 6.4.1. B. Braun Interventional Systems, Inc
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Application benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. BD
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Application benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Edwards Lifesciences Corporation
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Application benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Boston Scientific Corporation
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Application benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Getinge
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Application benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. TORAY INTERNATIONAL, INC.
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Application benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Stryker
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Application benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. BrosMed Medical Co., Ltd.
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Application benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. Medtronic
      • 6.4.9.1. Company overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Application benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Terumo Corporation
      • 6.4.10.1. Company overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Application benchmarking
      • 6.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. balloon valvuloplasty devices market, by Application, 2021 - 2033 (USD Million)
  • Table 3 U.S. balloon valvuloplasty devices market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Balloon Valvuloplasty Devices Market: market outlook
  • Fig. 10 U.S. Balloon Valvuloplasty Devices Market competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. balloon valvuloplasty devices market driver impact
  • Fig. 16 U.S. balloon valvuloplasty devices market restraint impact
  • Fig. 17 U.S. balloon valvuloplasty devices market strategic initiatives analysis
  • Fig. 18 U.S. balloon valvuloplasty devices market: Application movement analysis
  • Fig. 19 U.S. balloon valvuloplasty devices market: Application outlook and key takeaways
  • Fig. 20 Aortic Valve Stenosis market estimates and forecast, 2021 - 2033
  • Fig. 21 Pulmonary Valve Stenosis market estimates and forecast, 2021 - 2033
  • Fig. 22 U.S. Balloon Valvuloplasty Devices Market: End Use movement analysis
  • Fig. 23 U.S. Balloon Valvuloplasty Devices Market: End Use outlook and key takeaways
  • Fig. 24 Hospitals market estimates and forecast, 2021 - 2033
  • Fig. 25 Ambulatory Surgical Centers (ASCs) market estimates and forecast, 2021 - 2033
  • Fig. 26 Cardiac Catheterization Labs market estimates and forecast, 2021 - 2033